Abilify as an Adjunctive Treatment for Refractory Depression
Depressive DisorderMajorThis is a study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI) antidepressant treatment for depressed outpatients who are not responding fully to SSRI treatment alone. It is hypothesized that patients' functioning will improve after 12 weeks of treatment with Aripiprazole and SSRI medication.
Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression...
Major DepressionA doubleblind randomised trial with active versus sham rTMS in combination with escitalopram in patients with prior treatment resistant depression in an acute 12 weeks trial with subsequent 24 weeks study phase with active versus placebo citalopram
Lethargic Depression Study
EpilepsyMajor Depressive Disorder (MDD)This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana...
Depressive DisorderMajor1 moreAdolescents who are diagnosed with major depressive disorder are often also diagnosed with marijuana dependence. Fluoxetine is an antidepressant medication currently used to treat young people who are diagnosed with major depressive disorder. The purpose of this study is to determine the effectiveness of fluoxetine in treating adolescents and young adults diagnosed with both major depressive disorder and marijuana dependence.
Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder
Major Depressive DisorderThe purpose of this clinical research study is to learn whether BMS-562086 is both safe and effective in treating outpatients with major depressive disorder.
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
Depressive DisorderMajorThe purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
Major Depressive DisorderThis trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.
Major Depressive Disorder In The Elderly
Depressive DisorderMajorThis is a placebo-controlled study evaluating the effectiveness of medication in elderly subjects with Major Depressive Disorder (MDD).
Lexapro and Pramipexole and to Treat Major Depression
Major DepressionThis study compares the effectiveness of the combination of antidepressants: Lexapro and Pramipexole, with the effectiveness of each antidepressant alone. Purpose: Patients between 18 and 65 years of age with Major Depressive Disorder without psychotic features may be eligible for this 9-week study. Candidates must currently be in a major depressive episode of at least 4 weeks' duration, have failed to respond to treatment with an SSRI (Prozac, Zoloft, Paxil, Luvox, Celexa), and not have failed to respond to more than four antidepressants for the current episode. Candidates are screened with a physical examination, psychiatric evaluation, blood tests, review of vital signs, height and weight measurements, electrocardiogram (ECG), urine test for illegal drugs, and pregnancy test for women. Participants are tapered off antidepressants or other medications prohibited during the study and remain drug-free for 1 week before starting treatment. They are then randomly assigned to take pramipexole and escitalopram, pramipexole alone, or escitalopram alone for 6 weeks. During the study, participants come to the clinic eight times for health assessments and symptoms assessments, which include a check of vital signs and rating scales for depression and anxiety, adverse events, and sexual functioning. Blood and urine samples are collected periodically to monitor health, detect pregnancy in women, and detect illicit drug use. At the end of the 6-week treatment period, participants have a physical examination, ECG, blood test, and check of vital signs. Short-term anti-depressant treatment is offered, and plans are made for long-term treatment. Atendemos pacientes de habla hispana. ...
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
Major Depressive DisorderTo compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.